Equities
  • Price (EUR)103.05
  • Today's Change-0.85 / -0.82%
  • Shares traded--
  • 1 Year change-0.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.

  • Revenue in USD (TTM)7.60bn
  • Net income in USD1.08bn
  • Incorporated2001
  • Employees18.00k
  • Location
    Zimmer Biomet Holdings Inc345 E Main StWARSAW 46580-2746United StatesUSA
  • Phone+1 (574) 267-6131
  • Fax+1 (302) 636-5454
  • Websitehttps://www.zimmerbiomet.com/en
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ZBH:NYQ since
announced
Transaction
value
OrthoGrid Systems IncAnnounced07 Aug 202407 Aug 2024Announced-1.07%--
Video Interventionelle Medicale Scientifique SASAnnounced22 Feb 202422 Feb 2024Announced-15.54%--
Data delayed at least 15 minutes, as of Nov 22 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.